NetworkNewsBreaks – Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) Says Cigna will Cover ThyGenX® Nationwide
Interpace Diagnostics Group (NASDAQ: IDXG) has entered an agreement with Cigna to provide coverage of the company’s ThyGenX® test, effective immediately. Cigna is one of the largest national health plans in the United States, with 15 million members nationwide. This new agreement brings the number of individuals covered for Interpace’s ThyGenX™ molecular test for indeterminate thyroid nodules to approximately 275 million patients nationwide. “Cigna’s coverage of ThyGenX represents further acceptance among major health plans of our molecular products for Thyroid cancer. We are pleased that Cigna has joined the growing list of health plans that cover ThyGenX and that their…